To determine the frequency of ALK alterations (mutations and amplifications), their correlation with clinical characteristics, and their prognostic impact in HR-NB, we analyzed a large series of 1,092 diagnostic NB samples from patients on the HR-NBL1/SIOPEN trial. The gene discussed is ALK; the disease is neuroblastoma.